Glycomimetics Inc. buy tamam
Startpreis
17.10.17
/
50%
10,18 €
Kursziel
12.12.17
16,24 €
Rendite (%)
57,88 %
Endpreis
12.12.17
16,08 €
Zusammenfassung
Diese Einschätzung wurde am 12.12.17 mit einem Endkurs von 16,08 € beendet. Satte Gewinne von 57,88 % verzeichnete die BUY Einschätzung von tamam. tamam hat 50% Zuversicht bei dieser Einschätzung
Finanztrends
Rendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Glycomimetics Inc. | - | - | - | - |
| iShares Core DAX® | -0,56 % | 0,74 % | 14,81 % | 57,56 % |
| iShares Nasdaq 100 | -0,57 % | -0,32 % | 3,99 % | 86,02 % |
| iShares Nikkei 225® | 1,07 % | 5,62 % | 19,55 % | 49,34 % |
| iShares S&P 500 | 0,87 % | 0,03 % | 1,47 % | 58,07 % |
Kommentare von tamam zu dieser Einschätzung
In der Diskussion Glycomimetics Inc. diskutieren
GlycoMimetics Is An Exceptional Investment Opportunity
GMI-1271 shows impressive efficacy and safety profile (as of interim Phase 2).
Recent mixed shelf offering hints at major near-term upside potentials.
Longer term, GLYC seems to have found an important biomarker (E-selectin) that may expand TAM exponentially.
FDA Breakthrough Designation will expedite the development process.
Smart institutional investors are behind GLYC as significant long-term investors.
For the longer term, GLYC seems to have found an important biomarker that will allow it to expand into multiple tumor types (key opportunity is multiple myeloma - second largest blood cancer market) - significantly expanding its TAM. This will attract many players in oncology to partner/acquire GLYC once the company proves to be important in AML. In fact, GLYC is already running a Phase 1 trial inmultiple myeloma with GMI-1271 and management has started talking about this opportunity.Der Beitrag wurde gelöscht